Interestingly, the oncometabolite D-2-hydroxyglutarate (D2-HG), which could act as a nonspecific inhibitor of the iron- and αKG-dependent dioxygenases FTO and ALKBH5, accumulates in about 20% of AMLs [61], and may thus contribute to the outcome of these cancers by inhibiting RNA demethylation. The gene discussed is ALKBH5; the disease is cancer.